Meliora Therapeutics Raises $11M Seed Financing To Develop First Mechanism Of Action Atlas In Oncology
Meliora Therapeutics Raises $11M Seed Financing To Develop First Mechanism Of Action Atlas In Oncology
09/29/22, 12:02 PM
Location
san franciscoMoney raised
$11 million
Industry
biotechnology
Round Type
seed
Meliora Therapeutics, a biotech company pioneering a machine learning-driven platform to decipher oncology drugs’ true mechanisms-of-action, announced today the close of an $11M seed financing round led by HOF Capital and ZhenFund, with participation from Obvious Ventures, Village Global, BrightEdge (the impact investment arm of the American Cancer Society), Pebblebed (fund of Keith Adams, former Chief Architect at Slack), Axial, Olive Capital, and prominent individual investors Michael Polansky (co-founder of Parker Institute for Cancer Immunotherapy and ArsenalBio), Wes Sterman (founding investor for Gilead), and others.
Company Info
Location
san francisco, california, united states
Additional Info
Meliora is reimagining modern cancer drug development by putting genomics and cutting-edge computational approaches as first class principles of product development. The company has developed "molecular fingerprints" for tens of thousands of compounds in order to build an inference engine that identifies risk-adjusted small molecule compound and target mechanism of action (MOA) pairs. This proprietary discovery engine converts the existing world of optimized chemistry into an asset generating flywheel with high potential for clinical success. The company is headquartered in Menlo Park, CA. For more information, visit www.melioratx.com.